<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654340</url>
  </required_header>
  <id_info>
    <org_study_id>TSC 08-2018</org_study_id>
    <nct_id>NCT02654340</nct_id>
  </id_info>
  <brief_title>Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)</brief_title>
  <acronym>TuScCom</acronym>
  <official_title>Biomarkers for Tuberous Sclerosis Complex: An International Multicenter Observational Longitudinal Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CENTOGENE GmbH Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CENTOGENE GmbH Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, multicenter, observational, longitudinal study to identify biomarker/s for&#xD;
      Tuberous Sclerosis Complex and to explore the clinical robustness, specificity, and&#xD;
      long´-term variability of these biomarker/s&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tuberous Sclerosis Complex (TSC) is an autosomal dominant genetic disorder characterized by&#xD;
      the growth of numerous tumors in different body parts related to dysregulation of the&#xD;
      mechanistic target of rapamycin (mTOR) pathway. The overall incidence of TSC is estimated to&#xD;
      be as high as 1 in 6000 to 10,000 live birth.The main aspects of TSC that influence the&#xD;
      quality of life are associated with the brain: seizures, evelopmental delay, intellectual&#xD;
      disability, and autism. However, the incidence and severity of the various aspects of TSC can&#xD;
      vary widely.&#xD;
&#xD;
      TSC is generally caused by pathogenic variants in the tumor suppressor genes: TSC1 and TSC2.&#xD;
      Confirmation of a clinical diagnosis of tuberous sclerosis is performed via TSC1 and TSC2&#xD;
      sequencing.&#xD;
&#xD;
      There is no cure for TSC, therefore symptomatic therapy is the best possible choice,&#xD;
      including mTOR inhibitors, vigabatrin and other antiepileptic drugs for the seizures, and&#xD;
      neurosurgery in cases of life-threatening neurological symptoms.&#xD;
&#xD;
      The aim of the study is established TSC specific biomarker/s. Such biomarkers aim to&#xD;
      facilitate the diagnosis, treatment personalization and monitoring.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of TSC biomarker/s</measure>
    <time_frame>36 months</time_frame>
    <description>All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploring the clinical robustness, specificity, and longterm variability of TSC biomarker/s</measure>
    <time_frame>36 months</time_frame>
    <description>Samples will be analyzed for the candidate biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hypomelanotic Macules</condition>
  <condition>Facial Angiofibroma</condition>
  <condition>Shagreen Patches</condition>
  <condition>Ungual Fibromas</condition>
  <condition>Cortical Dysplasia</condition>
  <condition>Cardiac Rhabdomyoma</condition>
  <condition>Lymphangioleiomyomatosis</condition>
  <condition>Renal Angiomyolipoma</condition>
  <condition>Subependymal Giant Cell Astrocytoma</condition>
  <arm_group>
    <arm_group_label>Participants with Tuberous Sclerosis Complex (TSC)</arm_group_label>
    <description>Üarticipants diagnosed with Tuberous Sclerosis Complex (TSC) aged between 2 months and 50 years.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (Centocard®)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with Tuberous Sclerosis Complex (TSC)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Informed consent is obtained from the participant or from the parent / legal guardian&#xD;
&#xD;
          -  Participant is aged between 2 and 50 years&#xD;
&#xD;
          -  Diagnosis of TSC is genetically confirmed by CENTOGENE&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Participant is younger than 2 or older than 50 years&#xD;
&#xD;
          -  Diagnosis of TSC is not genetically confirmed by CENTOGENE&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Bauer, Prof.Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Centogene GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Center Mother Teresa</name>
      <address>
        <city>Tirana</city>
        <zip>10001</zip>
        <country>Albania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Alexandria University Children's Hospital</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Departmnet of Molecular and Medical Genetics, Tbilisi State Medical University</name>
      <address>
        <city>Tbilisi</city>
        <zip>0177</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Genetics, Amrita Institute of Medical Sciences &amp; Research Centre</name>
      <address>
        <city>Cochin</city>
        <state>Kerala</state>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rare diseases coordinating centre, Vilnius University Hospital Santaros klinikos</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Departmnet of Pediatric Gastroenterology and Hepatology, The Children's Hospital and Institute of Child Health</name>
      <address>
        <city>Lahore</city>
        <zip>54600</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Hospital for Children &quot;Louis Turcanu&quot;</name>
      <address>
        <city>Timişoara</city>
        <zip>300011</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lady Ridgeway Hospital for Children</name>
      <address>
        <city>Colombo</city>
        <zip>00800</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Albania</country>
    <country>Egypt</country>
    <country>Georgia</country>
    <country>India</country>
    <country>Lithuania</country>
    <country>Pakistan</country>
    <country>Romania</country>
    <country>Sri Lanka</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://www.centogene.com</url>
    <description>CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberous sclerosis complex</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Tuberous Sclerosis</mesh_term>
    <mesh_term>Lymphangioleiomyomatosis</mesh_term>
    <mesh_term>Angiomyolipoma</mesh_term>
    <mesh_term>Angiofibroma</mesh_term>
    <mesh_term>Fibroma</mesh_term>
    <mesh_term>Rhabdomyoma</mesh_term>
    <mesh_term>Malformations of Cortical Development</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

